1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Surgical Science Sweden AB (publ)

Surgical Science Sweden AB (publ)

SUSRF
Surgical Science Sweden AB (publ)US flagOther OTC
4.00
USD
- -
- -
204.10MMarket Cap
Surgical Science Sweden AB (publ)
SUSRF
(Other OTC)

Recent

price

4.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.9
3.62
2.97
2.7
3.6
3.05
8.63
15.8
17.33
17.33
19.45
19.15
Revenue per Share
0.07
0.23
-0.13
-0.19
0.45
0.45
2.03
3.7
4.59
2.58
1.31
1.02
Basic EPS, GAAP
-0.03
0.12
-0.06
-0.07
1.64
0.42
0.58
1.87
3.81
1.76
0.6
1.83
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.88
-1.45
-1.19
-1.13
-0.51
0.04
2.08
5.44
10.02
12.58
13.89
14.26
Book Value per Share
-0.36
-0.77
2.61
2.01
2.64
3.02
6.87
9.67
14.33
17.66
17.54
18.3
Tangible Book Value per Share
24
14
19
24
28
34
42
51
51
51
51
51
Basic Weighted Avg Shares
46
52
57
66
102
105
367
803
883
884
992
977
Sales/Revenue/Turnover
3.69
-0.44
-7.31
-6.19
14.95
19.06
15.41
20.25
21.43
16.32
6.94
6.95
Operating Margin (%)
7
9
10
10
15
17
34
52
56
61
83
- -
Depreciation Expense
2
3
-3
-5
13
16
86
188
234
132
67
52
Net Income, GAAP
- -
- -
- -
- -
17.38
20.62
- -
9.7
12.78
16.73
33.27
30.9
Effective Tax Rate (%)
3.47
6.3
-4.49
-6.88
12.41
14.89
23.52
23.42
26.5
14.89
6.73
5.34
Profit Margin (%)
11
2
45
44
73
102
385
520
756
913
892
919
Working Capital
22
19
4
4
2
2
12
15
40
57
56
- -
LT Debt
20
20
83
79
402
427
3,585
4,236
4,345
4,829
4,273
4,416
Total Equity
- -
- -
- -
- -
5.01
3.72
- -
3.73
3.8
2.57
0.99
1.05
Return on Invested Capital (%)
- -
- -
- -
- -
-71.67
-377.36
- -
96.64
55.75
21.83
9.69
7.42
Return on Capital (%)
- -
- -
- -
- -
- -
- -
192.41
103.09
59.49
22.85
9.89
7.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
56
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
4,679
1,608
1,378

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,121
1,185
1,187
Cash, Cash Equivalents & STI
597
616
668
Accounts Receivable, Net
144
137
123
Inventories
205
206
207
Total Current Liabilities
268
293
267
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
148.1%
151.97%
-11.51%
Free Cash Flow
-288.47%
67.79%
-66.04%
Net Income, GAAP
14.81%
100.42%
-49.24%
Sales/Revenue/Turnover
48.66%
78.24%
12.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
188
212
232
252
884
2025
251
209
264
269
992
2026
235
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.47
0.56
0.84
0.71
2.58
2025
0.65
-0.39
0.4
0.65
1.31
2026
0.37
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Total Brain Limited (TTBLF)
SpotLite360 IOT Solutions, Inc. (LITE.CN)
Kanamic Network Co.,LTD (3939.T)
Singular Health Group Ltd (SHG.AX)
Caduceus Software Systems Corp. (CSOC)
Nurosene Health Inc. (MNNDF)
Business
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training focused on laparoscopic, endoscopic, and team-based procedures. The company offers core products including LapSim for laparoscopic exercises ranging from basic navigation to advanced suturing, gynecology, hysterectomy, bariatrics, nephrectomy, cholecystectomy, and appendectomy; EndoSim for endoscopic training covering scope handling, tube functions, and loop reduction; TeamSim for procedure modules simulating real operating room environments to build team communication skills in crisis and routine situations; and customized simulation solutions for MedTech industry partners. Founded in 1997 and headquartered in Gothenburg, Sweden, Surgical Science operates globally across Europe, North and South America, Asia, and maintains research and development hubs in Tel Aviv, Israel; Stockholm, Sweden; and Seattle, USA, serving medical training centers, institutes, surgeons, and healthcare professionals worldwide. In December 2024, the company completed the acquisition of Intelligent Ultrasound Group PLC for approximately GBP 45.2 million, integrating its ultrasound simulation technologies including ScanNav Sim and HeartWorks to broaden the product portfolio, establish a UK research and development site in Cardiff, expand direct sales in the UK market, and more than double pro-forma ultrasound simulation revenues.

Company News

APIChat

  • seekingalpha.com

    Surgical Science Sweden AB (publ) (SUSRF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Surgical Science Sweden AB (publ) (SUSRF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Surgical Science Sweden AB (publ) (SUSRF) Analyst/Investor Day Transcript